

## Product Update

efavirenz 50mg, 100mg and 200mg hard capsules and 600mg film-coated tablets (Sustiva<sup>®</sup>) SMC No. (1125/15)

Bristol Myers Squibb

06 November 2015

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

**ADVICE:** following an abbreviated submission

**efavirenz (Sustiva<sup>®</sup>)** is accepted for use within NHS Scotland.

**Indication under review:** antiviral combination treatment of human immunodeficiency virus-1 (HIV-1) infected children aged 3 months to 3 years and weighing at least 3.5kg.

For patients at least 3 months old and weighing at least 3.5kg who cannot swallow capsules, the capsule contents can be administered with a small amount of food using the capsule sprinkle method of administration.

Efavirenz is listed in the British National Formulary for Children for the treatment of HIV infection.

### **Advice context:**

*No part of this advice may be used without the whole of the advice being quoted in full.*

*This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.*

*This assessment is based on data submitted by the applicant company up to and including 12 October, 2015.*

**Vice-Chairman  
Scottish Medicines Consortium**